Skip to main content

See also:

UAMS tests breast cancer vaccine on humans

Selected participants responded well to the breast cancer vaccine
Selected participants responded well to the breast cancer vaccine
UAMS

Doctors at the University of Arkansas for Medical Sciences (UAMS) are done with a Phase I breast cancer vaccine trial.

The breast cancer vaccine induced antibody responses in the "small group of participants who received five injections of the vaccine" in 23 weeks.Consequently, clinical vaccine collaborators Dr .Thomas Kieber-Emmons, PhD, and Dr. Laura Hutchins, M.D., are happy with the trial's success. Hutchins selected participants for the Phase I trial. Kieber-Emmons developed the vaccine at UAMS.

The trial at UAMS is the first time a breast cancer vaccine has been tested in humans outside of US military families. The human trial trumps research by others---from Dr. Vincent Tuohy in Cleveland to the United States Army. In October 2013, Tuohy found breast cancer vaccine success in lab mice. Tuohy needed funding for a Phase I trial. UAMS received its funding from a Clinical Translational Award from the Department of Defense Breast Cancer Program.

In 2012, the United States Army's Cancer Vaccine Development Program was set to begin Phase III trials in the beginning of 2013. You can read more about its program here.

Kieber-Emmons' peptide vaccine was designed to "trigger an immune response that destroys the cancer cells. The peptide (a computer generated chemical compound) "mimics carbohydrates that are attached to the cancer cells and tricks the immune system into attacking those carbohydrates" (UAMS).

Phase II of the trial begins in "the next few months to examine if the vaccine improves the efficacy of preoperative chemotherapy" (UAMS). In other words, Phase II seeks to determine whether or not the "combinaton of vaccine and standard chemotherapy improves the benefit from preoperative therapy."

Phase II participants includes a "larger number of women who are newly diagnosed with breast cancer."

The US Army in 2012 described the peptides in the breast cancer vaccine as "small pieces of the HER2/neu protein which the immune system can recognize and attack with T-cells." The army said that the military does not have as difficult of a time selecting participants for trials because army families are eager to help and are equally affected by cancer illness. Conversely, private participants are much more difficult to approve, according to Army researchers.